Abstract
Cardiovascular diseases represent a relevant problem worldwide. Data from World Health Organization (W.H.O.) demonstrate that they are one of the principle causes of death: 30% of all losses of human life throughout the world are due to heart diseases. Such data buries a substantial economic cost considering both the direct component, first of all the national health expense, and the indirect part, such as absenteeism rate, productivity loss, quality of life and, more generally, social costs. The future scenario pictured by the W.H.O. reveals a negative trend due to an increasing in the rate of morbidity and mortality especially in Emerging Countries. One of the solution to stem the costs – economic and not – connected to cardiovascular diseases is to empower the prevention activities overall the actions of primary prevention. This require a change in the traditional patient-physician relationship management model to get to an organizational model centred on patient and based on a proactive approach. In this perspective in the paper will be analysed the principal changes that occurred in the Italian national healthcare system and in particular the strategic plans and actions in theme of cardiovascular prevention.
Keywords: Prevention costs, organizational change, patient oriented model, disease management, cardiovascular risk assessment
Current Pharmaceutical Design
Title: Cardiovascular Disease: An Economical Perspective
Volume: 15 Issue: 10
Author(s): A. Lazzini and S. Lazzini
Affiliation:
Keywords: Prevention costs, organizational change, patient oriented model, disease management, cardiovascular risk assessment
Abstract: Cardiovascular diseases represent a relevant problem worldwide. Data from World Health Organization (W.H.O.) demonstrate that they are one of the principle causes of death: 30% of all losses of human life throughout the world are due to heart diseases. Such data buries a substantial economic cost considering both the direct component, first of all the national health expense, and the indirect part, such as absenteeism rate, productivity loss, quality of life and, more generally, social costs. The future scenario pictured by the W.H.O. reveals a negative trend due to an increasing in the rate of morbidity and mortality especially in Emerging Countries. One of the solution to stem the costs – economic and not – connected to cardiovascular diseases is to empower the prevention activities overall the actions of primary prevention. This require a change in the traditional patient-physician relationship management model to get to an organizational model centred on patient and based on a proactive approach. In this perspective in the paper will be analysed the principal changes that occurred in the Italian national healthcare system and in particular the strategic plans and actions in theme of cardiovascular prevention.
Export Options
About this article
Cite this article as:
Lazzini A. and Lazzini S., Cardiovascular Disease: An Economical Perspective, Current Pharmaceutical Design 2009; 15 (10) . https://dx.doi.org/10.2174/138161209787846883
DOI https://dx.doi.org/10.2174/138161209787846883 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Can Marine Omega 3 Fatty Acids Prevent and/or Treat Metabolic Syndrome?
Current Nutrition & Food Science Pharmacokinetic-Pharmacodynamic Modeling of Antihypertensive Drugs: From Basic Research to Clinical Practice
Current Hypertension Reviews Editorial (Thematic Issue: Medication Management for People with Dementia or Cognitive Impairment)
Current Clinical Pharmacology Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial
Reviews on Recent Clinical Trials Mass Spectrometry Data Analysis in the Proteomics Era
Current Bioinformatics Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Current Pharmaceutical Design Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries
Current Pharmacogenomics and Personalized Medicine Lipid Management for the Prevention of Cardiovascular Disease
Current Pharmaceutical Design Metabolism of Rhaponticin and Activities of its Metabolite, Rhapontigenin: A Review
Current Medicinal Chemistry Possible Therapeutic Targets in Cardiac Myocyte Apoptosis
Current Pharmaceutical Design Omega-3 Fatty Acids in the Management of Epilepsy
Current Topics in Medicinal Chemistry Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology Influence of Lifestyle Measures on Hypertriglyceridaemia
Current Drug Targets Dietary and Plant Polyphenols Exert Neuroprotective Effects and Improve Cognitive Function in Cerebral Ischemia
Recent Patents on Food, Nutrition & Agriculture The Current Role of Statin Therapy in the Treatment of Atrial Fibrillation
Cardiovascular & Hematological Agents in Medicinal Chemistry Serum Vitamin D Concentration and Potential Risk Factors for its Deficiency in HIV Positive Individuals
Current HIV Research Clopidogrel, Aspirin and Proton Pump Inhibition after Percutaneous Valve Implants: An Update
Current Pharmaceutical Design Therapeutic Targeting of P-Selectin in Atherosclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Clinical Relevance of Non-Fasting and Postprandial Hypertriglyceridemia and Remnant Cholesterol
Current Vascular Pharmacology